Eric Swayze - 02 Jan 2026 Form 4 Insider Report for IONIS PHARMACEUTICALS INC (IONS)

Role
EVP Research
Signature
By: Patrick R. O'Neil, attorney-in-fact For: Eric Swayze
Issuer symbol
IONS
Transactions as of
02 Jan 2026
Net transactions value
-$427,662
Form type
4
Filing time
06 Jan 2026, 17:35:26 UTC
Previous filing
16 Oct 2025
Next filing
20 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Swayze Eric EVP Research 2855 GAZELLE COURT, CARLSBAD By: Patrick R. O'Neil, attorney-in-fact For: Eric Swayze 05 Jan 2026 0001791058

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IONS Common Stock Options Exercise $312,061 +5,125 +17% $60.89 35,578 02 Jan 2026 Direct
transaction IONS Common Stock Sale $402,671 -5,125 -14% $78.57 30,453 02 Jan 2026 Direct F1, F2
transaction IONS Common Stock Options Exercise $1,116,601 +18,338 +60% $60.89 48,791 02 Jan 2026 Direct
transaction IONS Common Stock Sale $1,453,653 -18,338 -38% $79.27 30,453 02 Jan 2026 Direct F1, F3
holding IONS Common Stock 256 02 Jan 2026 by Son

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IONS Non-Qualified Stock Option (right to buy) Options Exercise $0 -5,125 -19% $0.000000 22,403 02 Jan 2026 Common Stock 5,125 $60.89 Direct
transaction IONS Non-Qualified Stock Option (right to buy) Options Exercise $0 -18,338 -82% $0.000000 4,065 02 Jan 2026 Common Stock 18,338 $60.89 Direct
transaction IONS Non-Qualified Stock Option (right to buy) Award $0 +19,350 $0.000000 19,350 02 Jan 2026 Common Stock 19,350 $79.67 Direct F4
transaction IONS Non-Qualified Stock Option (right to buy) Award $0 +150 $0.000000 150 02 Jan 2026 Common Stock 150 $79.67 by Son F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on August 14, 2024.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.155 to $78.88 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.88 to $79.70 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.
F4 Grant on 01/02/2026 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 01/02/2026. 25% of the shares subject to the option will vest and become exercisable on 01/02/2027. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years.
F5 Grant on 01/02/2026 to reporting person's son of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 01/02/2026. 25% of the shares subject to the option will vest and become exercisable on 01/02/2027. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years.